Lyell Immunopharma, Inc. Increase (Decrease) in Contract with Customer, Liability
Lyell Immunopharma, Inc. (LYEL) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-03-11
- Lyell Immunopharma, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was $0.00.
- Lyell Immunopharma, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was $0.00.
- Lyell Immunopharma, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-03-31 was $0.00.
- Lyell Immunopharma, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- Lyell Immunopharma, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
- Lyell Immunopharma, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$84.65M.
- Lyell Immunopharma, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$10.51M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-11 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | -$48.35M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | -$48.35M derived: sum of 3 quarters · filed 2025-03-11 | -$48.35M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | -$48.35M derived: sum of 2 quarters · filed 2025-03-11 | -$48.35M derived: sum of 3 quarters · filed 2025-03-11 | -$84.09M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | -$48.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$48.35M derived: sum of 2 quarters · filed 2025-03-11 | -$84.09M derived: sum of 3 quarters · filed 2025-03-11 | -$84.65M 10-K · filed 2025-03-11 |
| 2022-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$35.74M derived: sum of 2 quarters · filed 2023-11-07 | -$36.30M 10-Q · filed 2023-11-07 | -$39.11M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$35.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$36.30M 10-Q · filed 2023-08-08 | -$39.11M derived: sum of 3 quarters · filed 2024-02-28 | -$41.75M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$558.00K 10-Q · filed 2023-05-04 | -$3.37M derived: sum of 2 quarters · filed 2024-02-28 | -$6.01M derived: sum of 3 quarters · filed 2024-02-28 | -$8.63M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$5.45M derived: sum of 2 quarters · filed 2024-02-28 | -$8.07M derived: sum of 3 quarters · filed 2024-02-28 | -$10.51M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$5.26M derived: sum of 2 quarters · filed 2022-11-08 | -$7.70M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$5.06M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$2.44M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$7.76M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $102.92M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |